ParaMedir, an innovative medical technology company based in the Northern Netherlands, is proud to announce the significant EFRO subsidy of about €600,000.00 awarded by SNN (Samenwerkingsverband Noord-Nederland). This subsidy will support a groundbreaking consortium led by ParaMedir in their mission to improve healthcare through innovative (bio)monitoring solutions. Next to the subsidy granted by the SNN, the province of Groningen and the municipality of Groningen have both agreed to finance this project as well, contributing about €130,000.00, underlining the importance of this project for the region.
The consortium, consisting of valued partners including the University Medical Centre Groningen (UMCG), Health Hub Roden, and GitGud Software Development, aims to address the urgent challenge of diagnosing and monitoring patients with acute heart failure. Acute heart failure affects 25 million patients globally, with rising incidence and high hospitalization rates. The readmission rate is alarming, and the mortality rate is significant. The standard treatment approach involves restoring the patient's fluid balance using diuretics to eliminate salt and fluid from the patient's body. Currently, treatment of acute heart failure relies on frequent urine collections analyzed through conventional methods.
Cardiodrop©, a groundbreaking innovation, will enable rapid and frequent bedside urine analysis. Building on ParaMedir’s proprietary technology, CardioDrop© will be optimized for use in acute heart failure patients. It facilitates personalized treatment in cardiac care units (CCUs) and intensive care units (ICUs) by monitoring biomarkers and electrolytes. Cardiodrop's implementation in CCUs and ICUs will significantly enhance the quality of life for acute heart failure patients and their caregivers. It will reduce mortality rates, readmissions, and healthcare costs. Additionally, it enables early detection and treatment of renal failure, revolutionizing care provision and improving well-being.
The EFRO subsidy awarded by SNN in the Northern Netherlands is a proof of the consortium's dedication to advancing medical technology and improving patient care. ParaMedir extends its gratitude to SNN and the consortium partners for their commitment and collaborative efforts.
ParaMedir is an innovative medical technology company based in the North of the Netherlands. By developing innovative (bio)monitoring solutions that seamlessly integrate into patient care, ParaMedir aims to revolutionize the healthcare industry. Through the fusion of two promising technologies - biosensing and microfluidics - Paramedir has developed a robust platform that enables real-time continuous monitoring of crucial biomarkers. The first product in development is UriMoni™, a diagnostic device developed for bedside monitoring and prediction of Acute Kidney Injury (AKI).
UriMoni™ and CardioDrop© comprises an array of micro(bio)sensors that monitor relevant biomarkers. These electrochemical micro(bio)sensors, assembled based on extensive ParaMedir intellectual property, provide selective and sensitive measurements of key urinary biomarkers. Proprietary algorithms convert the electrochemical output into biochemical and clinically relevant information, enabling doctors to assess kidney function for the diagnosis and monitoring of acute kidney injury (AKI) and acute heart failure (AHF).
ParaMedir envisions a future where the obtained information is seamlessly uploaded to the hospital management system (HIS), making it accessible to relevant clinical personnel at any given time. Additionally, the integration of AI solutions holds the potential for predicting kidney function and managing AKI and AHF more effectively. The higher temporal resolution of kidney function biomarkers allows for the detection of short-term changes, leading to improved management strategies. For more information about ParaMedir and its revolutionary products, please visit www.Paramedir.nl
Source article and picture: Paramedir
MimeCure heeft een investering van 3 miljoen euro binnengehaald voor de ontwikkeling van een regeneratief geneesmiddel voor de behandeling van chronische longziekten, zoals longfibrose. Dankzij deze financiering kan MimeCure de afronding van de preklinische fase versnellen en beginnen met de voorbereidingen voor klinische proeven, die volgens planning eind 2027 van start zullen gaan. De investeringsronde wordt geleid door Addington Investment Group en ondersteund door mede-investeerder Apsara Investments.
Turning plans into results: that is the central focus of the fifth LIFE Science Conference, taking place on Tuesday, 22 September 2026 at Forum Groningen. The LIFE Cooperative will bring together professionals, entrepreneurs, researchers and policymakers from the life sciences and health sector around one key question: how do we translate vision into concrete impact? The keynote speaker will be Peter Wennink, former CEO of ASML and one of the most influential leaders in the Dutch technology sector. In 2025, he presented his advisory report ‘The Road to Future Prosperity’, in which he advocates targeted investments in innovation to strengthen the Netherlands’ long-term earning capacity.
In the North, and in Groningen in particular, there are dozens of companies working on innovations in the fields of life sciences and health. There are many hidden gems among them, says Ronald Hesse, director of the LIFE Cooperative partnership. “Millions of patients worldwide have already benefited from innovations developed here in Groningen,” he says.
